PharmaCyte Biotech 관리
관리 기준 확인 3/4
PharmaCyte Biotech's CEO is Josh Silverman, appointed in Oct 2022, has a tenure of 2.08 years. total yearly compensation is $787.92K, comprised of 46.3% salary and 53.7% bonuses, including company stock and options. directly owns 0.65% of the company’s shares, worth $91.50K. The average tenure of the management team and the board of directors is 6 years and 2.8 years respectively.
주요 정보
Josh Silverman
최고 경영자
US$787.9k
총 보상
| CEO 급여 비율 | 46.3% |
| CEO 임기 | 2.1yrs |
| CEO 소유권 | 0.7% |
| 경영진 평균 재임 기간 | 6yrs |
| 이사회 평균 재임 기간 | 2.8yrs |
최근 관리 업데이트
Recent updates
PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business
Mar 22
PharmaCyte Biotech says CEO to step down, announces strategic review of business
Oct 07PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors
Aug 15Is This A Good Time To Invest In PharmaCyte?
Jan 07PharmaCyte Biotech: Buy The 'Dump'
Aug 21CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jul 31 2024 | n/a | n/a | US$4m |
| Apr 30 2024 | US$788k | US$365k | -US$17m |
| Jan 31 2024 | n/a | n/a | -US$15m |
| Oct 31 2023 | n/a | n/a | -US$10m |
| Jul 31 2023 | n/a | n/a | -US$10m |
| Apr 30 2023 | US$198k | US$188k | -US$4m |
보상 대 시장: Josh's total compensation ($USD787.92K) is about average for companies of similar size in the US market ($USD655.65K).
보상과 수익: Josh's compensation has been consistent with company performance over the past year.
CEO
Josh Silverman (54 yo)
2.1yrs
테뉴어
US$787,923
보상
Mr. Joshua N. Silverman, also known as Josh, is Independent Chairman of the Board of Petros Pharmaceuticals, Inc. Mr. Joshua N. Silverman, also known as Josh, serves as an Independent Director at Femasys I...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Interim CEO | 2.1yrs | US$787.92k | 0.65% $ 91.5k | |
| Chief Financial Officer | 7.7yrs | US$586.56k | 0.14% $ 19.0k | |
| Consulting Chief Medical Officer | 4.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Medical & Scientific Advisory Board and Consultant | 9yrs | 데이터 없음 | 데이터 없음 |
6.0yrs
평균 재임 기간
66yo
평균 연령
경험이 풍부한 관리: PMCB's management team is seasoned and experienced (6 years average tenure).
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Interim CEO | 2.3yrs | US$787.92k | 0.65% $ 91.5k | |
| Member of Medical & Scientific Advisory Board and Consultant | 9yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 2yrs | US$290.00k | 0% $ 0 | |
| Member of Medical & Scientific Advisory Board | 8.5yrs | 데이터 없음 | 데이터 없음 | |
| Chairman of Medical & Scientific Advisory Board | 2.8yrs | US$16.76k | 데이터 없음 | |
| Independent Director | 7.3yrs | US$296.00k | 0.036% $ 5.1k | |
| Independent Director | 1.9yrs | US$265.00k | 0% $ 0 | |
| Member of Medical & Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 2.3yrs | US$290.00k | 0.65% $ 91.5k | |
| Member of Medical & Scientific Advisory Board | 5.3yrs | 데이터 없음 | 데이터 없음 |
2.8yrs
평균 재임 기간
64.5yo
평균 연령
경험이 풍부한 이사회: PMCB's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.